The emergence of multidrug-resistant pathogens represents a critical challenge for clinicians managing vulnerable pediatric populations. Carbapenem-resistant Enterobacterales cause severe invasive infections with high mortality in hospitalized infants and children. Historically, surveillance programs focused primarily on adult populations, creating major gaps in pediatric epidemiology. However, recent multicenter surveillance data on pediatric CP-CRE from 2019 through 2024 provide vital clarity regarding clinical trends and microbiological profiles. Consequently, healthcare providers must recognize these pediatric patterns to anticipate emerging threats. Therefore, evaluating contemporary pediatric epidemiological data allows clinicians to update empiric prescribing protocols and strengthen infection prevention practices.

Understanding the Emergence of Pediatric CP-CRE

Clinicians in tertiary centers face increasing difficulty when treating multidrug-resistant Gram-negative bacterial infections in children. Strains producing carbapenemase enzymes hydrolyze almost all beta-lactams, including carbapenems. Therefore, pediatric CP-CRE infections limit therapeutic options and prolong hospitalizations. While prior studies focused on adult cohorts, pediatric patients exhibit distinct physiological dynamics and exposure risks. The multi-year analysis by Rankin and colleagues provides essential insights into pediatric carbapenemase epidemiology.

Furthermore, children who develop resistant infections frequently have severe underlying conditions. For instance, infants with congenital heart disease, intestinal failure, or solid organ transplants undergo frequent invasive interventions. Consequently, indwelling medical hardware and prior antibiotic courses select for resistant colonizing organisms. Pathogens such as Klebsiella pneumoniae and Enterobacter cloacae complex readily acquire mobile resistance elements. In addition, horizontal plasmid transfer facilitates the rapid dissemination of carbapenemase genes among enteric flora. Because young children possess immature immune defenses, colonization often progresses to severe invasive sepsis. Hence, healthcare teams must understand these pediatric dynamics to prevent adverse clinical outcomes.

Surveillance Trends Across Age Groups and Clinical Sources

Surveillance data between 2019 and 2024 reveal important demographic disparities in pediatric carbapenem resistance. Notably, infants under one year of age consistently demonstrate the highest infection rates among children. This disproportionate burden reflects the heightened vulnerability of neonatal intensive care populations. Preterm neonates endure prolonged hospitalizations where invasive supportive technologies are necessary for survival. Furthermore, central vascular lines, endotracheal tubes, and urinary catheters disrupt protective epithelial barriers.

Meanwhile, older children with complex chronic diseases also face elevated colonization risks. The surveillance data demonstrated that urinary tract isolates represent the majority of pediatric specimens, followed by bloodstream infections. Although bacteremia occurs less frequently than urinary infections, it causes substantial morbidity and septic shock. In addition, epidemiologists observed notable variations between healthcare-associated community-onset cases and pure nosocomial transmissions. While most cases involve recent hospital contact, community-onset cases without prior admissions are gradually rising. Therefore, clinicians must maintain diagnostic vigilance across outpatient clinics, emergency departments, and intensive care units alike.

Molecular Mechanisms and Regional Enzymatic Diversity

Understanding the biochemical mechanisms driving carbapenem resistance is essential for designing effective pediatric therapies. Resistance primarily develops through non-carbapenemase mechanisms, such as porin mutations with extended-spectrum beta-lactamases, or direct carbapenemase enzyme production. However, carbapenemase producers cause greater concern because mobile plasmids facilitate rapid horizontal dissemination. Molecular testing reveals considerable diversity among circulating pediatric strains across healthcare regions.

Historically, serine carbapenemases like Klebsiella pneumoniae carbapenemase predominated in North American hospitals. Nevertheless, recent surveillance documents an increase in metallo-beta-lactamases, particularly New Delhi metallo-beta-lactamase, alongside OXA-48-like enzymes. This changing microbiological distribution directly alters therapeutic decision-making. Metallo-beta-lactamases hydrolyze novel beta-lactamase inhibitor combinations, rendering standard new agents ineffective. Clinicians in South Asia and India have combated metallo-beta-lactamase predominance for years, highlighting the global nature of this crisis. Consequently, hospital laboratories must implement molecular testing to track enzymatic shifts and guide mechanism-targeted antibiotic selection.

Infection Prevention Challenges in Neonatal and Pediatric ICUs

Containing carbapenemase-producing organisms within neonatal and pediatric intensive care units demands rigorous infection prevention measures. Because neonates possess immature mucosal immunity and fragile skin, pathogens spread readily through direct contact. Transient hand carriage by healthcare staff remains a primary transmission route during nursing care. Therefore, strict hand hygiene compliance and dedicated contact precautions are vital.

Furthermore, units must implement cohorting strategies when caring for colonized or infected infants. Environmental reservoirs also contribute substantially to sustained hospital transmission. Strains of Klebsiella and Enterobacter form persistent biofilms within moist hospital fixtures, such as sink drains and wash basins. Consequently, environmental services must execute regular, validated disinfection protocols in high-risk nursery areas. In addition, invasive devices require relentless clinical re-evaluation. Physicians must promptly remove unnecessary central lines, urinary catheters, and mechanical ventilation circuits as soon as patients stabilize. By combining active surveillance screening with strict environmental controls, pediatric units can successfully protect vulnerable children from life-threatening nosocomial infections.

Diagnostic Pathways and Targeted Therapeutic Approaches

Rapid diagnostic differentiation between carbapenemase producers and non-producers directly impacts pediatric outcomes. Relying exclusively on standard automated susceptibility testing delays optimal treatment by several days. During this critical interval, ineffective empiric therapy markedly increases mortality in pediatric septic shock. Fortunately, rapid phenotypic assays and multiplex molecular polymerase chain reaction panels identify specific resistance mechanisms within hours. In addition, lateral flow immunochromatographic assays detect KPC, NDM, and OXA-48 enzymes directly from positive blood culture bottles.

Once laboratories confirm the carbapenemase class, clinicians can initiate pathogen-directed therapy. For KPC producers, preferred options include ceftazidime-avibactam or meropenem-vaborbactam. Conversely, metallo-beta-lactamase producers require synergy regimens, such as ceftazidime-avibactam co-administered with aztreonam, or cefiderocol monotherapy. However, many newer beta-lactams lack pediatric dosing data. Therefore, pediatricians must collaborate closely with infectious disease pharmacists to optimize weight-based dosing. Furthermore, antimicrobial stewardship programs must restrict unnecessary carbapenem usage for uncomplicated pediatric infections, thereby preserving essential reserve antimicrobials for severely ill children.

Frequently Asked Questions

Which pediatric patient groups face the highest risk for carbapenemase-producing Enterobacterales infections?

Critically ill neonates in intensive care units and infants under one year of age face the highest risk. Additionally, pediatric patients with complex medical conditions, prior broad-spectrum antibiotic exposure, indwelling urinary catheters, or central venous lines exhibit elevated vulnerability. Furthermore, prolonged hospitalization and surgical procedures facilitate colonization by multidrug-resistant pathogens. Clinicians must maintain high clinical suspicion when these high-risk children present with sudden clinical deterioration, unexplained fever, or healthcare-associated sepsis.

How should clinicians treat pediatric infections caused by metallo-beta-lactamase producing organisms?

Treating pediatric metallo-beta-lactamase infections requires specific combination therapy because standard novel beta-lactamase inhibitor agents fail against these enzymes. Infectious disease specialists frequently utilize aztreonam combined with ceftazidime-avibactam to overcome metallo-beta-lactamase hydrolysis while protecting aztreonam from concomitant beta-lactamases. Alternatively, cefiderocol represents a valuable option where approved. Because pediatric dosing regimens and pharmacokinetics vary significantly with age, physicians must collaborate closely with clinical pharmacists to monitor therapeutic efficacy, adjust dosages, and minimize organ toxicities.

Why is rapid molecular or phenotypic carbapenemase testing critical for pediatric management?

Rapid carbapenemase characterization is vital because phenotypic resistance alone does not identify the underlying enzymatic mechanism. Different carbapenemases require completely divergent therapeutic strategies. For example, ceftazidime-avibactam effectively treats KPC-producing bacteria but exhibits zero activity against metallo-beta-lactamases. Consequently, rapid molecular or lateral flow identification prevents ineffective empirical therapy and reduces mortality in severe infections. Moreover, rapid detection triggers immediate hospital infection control precautions, preventing uncontained nosocomial transmission across neonatal and pediatric intensive care units.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Rankin DA et al. Carbapenemase-Producing Carbapenem-Resistant Enterobacterales Among Children in the United States, 2019-2024. J Pediatric Infect Dis Soc. 2026 Nov 04. doi: undefined. PMID: 42980645.
2. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024;79(5):e1-e35.
3. Indian Council of Medical Research. Treatment Guidelines for Antimicrobial Use in Common Syndromes. New Delhi: ICMR; 2022.